Presentations

CORPORATE PRESENTATION

2024

  • LATEST
  • 2023
  • 2022
  • 2021
  • ARCHIVE
  • R&D Day 2024

  • H1 FY2024 Financial Results

  • 34th Ordinary General Meeting of Shareholders

  • FY2023 Financial Results Presentation

  • 42nd Annual J.P. Morgan Healthcare Conference

  • Jefferies London Healthcare Conference 2023

  • R&D Day

  • H1 FY2023 Financial Results

  • Acquisition of Idorsia’s Pharmaceuticals Business in Japan and APAC (ex China)

  • 33rd Ordinary General Meeting of Shareholders

  • Top Interview - Stock Voice TV (Japanese only)

  • FY2022 Financial Results Presentation

  • 41st J.P. Morgan Healthcare Conference

  • Jefferies London Healthcare Conference

  • IR seminar for individual investors (Japanese only) - Sosei's Business Overview

  • R&D Day

  • IR seminar for individual investors (Japanese only) - Intrroduction for Biotechnology Sector

  • H1 FY2022 Financial Results Presentation

  • 32nd Ordinary General Meeting of Shareholders

    PDF
  • FY2021 Financial Results Presentation

  • 40th Annual J.P. Morgan Healthcare Conference

  • Investor Webinar Q&A; - Collaboration with Neurocrine Biosciences to Develop Novel Muscarinic Receptor Agonists

  • Collaboration with Neurocrine Biosciences to Develop Novel Muscarinic Receptor Agonists

  • Jefferies London Healthcare Conference 2021 Presentation

  • H1 FY2021 Financial Results Presentation

  • UBS Global Healthcare Virtual Conference 2021

  • Online briefing session for investors (in Japanese)

  • 31st Ordinary General Meeting of Shareholders

    PDF
  • FY2020 Financial Results Conference Call

  • FY2020 Financial Results Presentation

  • 39th Annual J.P. Morgan Healthcare Conference

  • Regains Muscarinic Agonist Programs

  • Coronavirus Program Update

    PDF
  • H1 FY2020 Financial Results Presentation

  • New Discovery Collaboration With AbbVie (Japanese only)

  • 30th Ordinary General Meeting of Shareholders

  • FY2019 Financial Results Presentation

  • 38th Annual J.P. Morgan Healthcare Conference

  • Investor R&D Day Presentation - Malcolm Weir, EVP Chief R&D Officer

  • Investor R&D Day Presentation - Chris de Graaf Director, Head of Computational Chemistry

  • Investor R&D Day Presentation - Stacey Southall Associate Director, Head of Biophysics

  • Investor R&D Day Presentation - Rie Suzuki - Director, Translational Sciences

  • Investor R&D Day Presentation - Professor Yoshinori Fujiyoshi (Japanese Only)

  • Investor R&D Day Webcast

  • H1 FY2019 Financial Results Presentation

  • Individual Shareholders Briefing (Japanese only)

  • 29th Ordinary General Meeting of Shareholders

  • Individual Shareholders Briefing (Japanese only)

  • FY2018 Financial Results (Nine-month period ended December 31, 2018) Presentation (with note)

  • FY2018 Financial Results (Nine-month period ended December 31, 2018) Presentation